CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Gilead agrees to buy HongShan-backed developer’s HCXT-2001 program for USD 1.28 billion upfront

By Public Technologies
  • Gilead agreed on October 22, 2026, to acquire 瀚辰星泰’s Phase I oral IL-23R program for USD 1.28 billion upfront.
  • 迪哲医药 received USD 600 million upfront as ZEGFROVY launched in the US; 剂泰科技 secured Lilly collaboration milestones worth up to USD 1.1 billion.
  • 英矽智能 reached its first Servier research milestone; 杉泽生物 obtained exclusive rezafungin development and commercialization rights in mainland China, Hong Kong and Macau.
  • 心泰医疗 secured Chinese clearance for its PFO occluder; 同心医疗 completed Würzburg’s first BrioVAD implantation; 辐联科技 presented initial human FL-261 imaging data.
  • 精锋医疗 obtained EU certification for its remote surgery system; 衍微科技 gained national “Little Giant” recognition; 艾柯医疗 entered the priority tier.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HongShan Capital (Hong Kong) Ltd. published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.